Evidence Level
Quercetin is a prominent compound in longevity research, recognized for its anti-inflammatory and antioxidant properties. It gained significant attention as part of the D+Q protocol, a first-in-human senolytic treatment tested in diabetic kidney disease patients by Kirkland et al. (2019). Subsequent studies have expanded on its benefits: Serban et al. (2016) confirmed its role in lowering blood pressure through a meta-analysis, while Mohammadi-Sartang et al. (2017) demonstrated its anti-inflammatory effects across multiple randomized controlled trials.
Recent research highlights advancements in quercetin's bioavailability. Liu et al. (2025) conducted a systematic review and meta-analysis of 31 human studies, revealing that specific chemical modifications and dietary factors significantly enhance absorption. This improvement addresses the compound's previously noted limitation of poor bioavailability in standard forms.
Additionally, quercetin has shown therapeutic potential across various conditions. Wu et al. (2025) found it effective in mitigating pulmonary fibrosis in animal models, while Bian et al. (2025) demonstrated its ability to reduce hyperuricemia by modulating oxidative stress and lipid metabolism. Su et al. (2024) highlighted its comparable efficacy to metformin in improving metabolic markers in polycystic ovary syndrome animal models.
Overall, quercetin's versatility and recent advancements in delivery mechanisms underscore its potential as a valuable therapeutic agent across multiple health domains.